Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)
NCT06926790Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Feb 2025
- Primary completion
- Mar 2030
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in non-small cell lung cancer (NSCLC), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Pathological Complete Response. Started Feb 2025; status: recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06926790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06926790.